Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q1 2019 Arbutus Biopharma Corp Earnings Call Transcript

May 06, 2019 / 08:30PM GMT
Release Date Price: $2.63 (+0.77%)
Operator

Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Ms. Pam Murphy. Ma'am, you may begin.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Thank you. Good afternoon, and thank you all for joining us. On the call today from the Arbutus management team are Dr. Mark Murray, Chief Executive Officer; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and Dave Hastings, Chief Financial Officer.

Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline, including clinical time lines and results for our lead compounds AB-506, AB-729 and AB-452, our expected cash runway and expected revenues from our current and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot